Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief Summary: The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel \[C/P\]) and continued as maintenance therapy compared with chemotherapy alone.


Options:
A: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: PLD, Biological: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Research Arm | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): Research Arm | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Research Arm
B: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin
C: Arm Label: Placebo + Carboplatin + Paclitaxel -> Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Placebo; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Veliparib; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: OTHER; Name: Placebo to Veliparib; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo
D: Arm Label: Arm I (bevacizumab and everolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Everolimus, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (bevacizumab and placebo); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm I (bevacizumab and everolimus) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (bevacizumab and placebo)

Answer: C